Terbinafine vs. placebo for onychomycosis in black patients.
Billstein
S
S
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA.
Kianifard
F
F
Justice
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D044383:Black People; D004311:Double-Blind Method; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D014009:Onychomycosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D010919:Placebos; D000077291:Terbinafine; D013997:Time Factors; D016896:Treatment Outcome; D014249:Trichophyton / Q000187:drug effects / Q000302:isolation & purification
D000935:Antifungal Agents; D009281:Naphthalenes; D010919:Placebos; D000077291:Terbinafine